Introduction
============

Endoscopic ultrasound (EUS) is a well-established, cost-effective procedure for investigating solid pancreatic mass lesions [@JR362-1] [@JR362-2]. While CT scan is the primary modality for investigating pancreatic disease, EUS is the preferred tool in highly suspicious circumstances due to its ability to reveal lesions in the absence of a mass on CT scan [@JR362-3] and its superior performance characteristics for diagnosing lesions less than 30 mm in size [@JR362-4]. Between 2006 and 2010, the usage of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) increased by 69.3 %; percutaneous biopsy increased by 1.8 % compared to a corresponding decrease in open surgical biopsy by 41.7 % [@JR362-1]. With the growing utilization of EUS-FNA [@JR362-5], there is a renewed focus to evaluate and target small lesions as early stage diagnosis leads to more curative resections and significantly impacts clinical outcomes.

Although EUS-FNA has a high sensitivity and specificity for diagnosis of pancreatic mass lesions, diagnostic accuracy of EUS-FNA is dependent on operator experience [@JR362-6], presence of rapid on-site cytopathologist evaluation (ROSE) [@JR362-7], needle size [@JR362-8], and the presence of chronic pancreatitis [@JR362-9]. In the presence of a mass and high clinical suspicion but a negative EUS-FNA, there is also evidence that repeat EUS-FNA improves diagnostic accuracy [@JR362-10]. Even though a recent meta-analysis confirmed that diagnostic accuracy is superior in the presence of ROSE [@JR362-7], suboptimal EUS-FNA performance was noted for pancreatic mass sizes at either end of the spectrum. A study from 1999 [@JR362-11] showed that the sensitivity of EUS-FNA for small lesions was modest while another study showed that diagnostic accuracy rises as the size of the mass increases with a reduction in accuracy for lesions more than 40 mm [@JR362-12]. While additional endoscopic ultrasound imaging features may aid in the differentiation between solid pancreatic mass lesions [@JR362-13] and are helpful for predicting the possibility of adenocarcinoma [@JR362-14], tissue diagnosis is essential for further clinical management.

Given the importance of pancreatic mass size for staging, increasing use of EUS-FNA for tissue acquisition and uncertainty with regard to its performance at different mass sizes, we sought to study the operating characteristics of EUS-FNA vis-à-vis pancreatic mass size under gold standard conditions.

Materials and methods
=====================

Patient population
------------------

This is a retrospective clinicopathologic correlation study of patients who underwent EUS-FNA of pancreatic masses from July 2000 to March 2013. Data including EUS findings, rapid on-site cytopathology, and final histology were documented in an institutional review board (IRB) approved database. After identifying all patients who had final histology as the gold standard for diagnosis, the available cohort was stratified into four groups based on longest dimension of cross-sectional pancreatic mass size -- Group A (≤ 10 mm), Group B (11 -- 20 mm), Group C (21 -- 40 mm), and Group D (\> 40 mm). These four groups were compared for the operating characteristics of EUS-FNA.

Procedure
---------

EUS was performed under moderate sedation or anesthesia with a linear array echoendoscope (Olympus UCT140, Olympus America Corp, Center Valley, PA, United States) utilizing the standard station approach by four experienced endosonographers. When a mass was identified, cross-sectional size measurements were undertaken along with echo features, surrounding vasculature, evaluation for peripancreatic lymph nodes, and examination of the liver. Fine needle aspiration (FNA) of the mass was performed with a standard FNA needle (Echotip, Cook Endoscopy, Winston-Salem, NC, United States; Expect™, Boston Scientific Corporation, Natick, MA, United States); the size of the needle (25G, 22G, and 19G) used was determined by individual choice of the endosonographer. Patients then recovered as per standard procedure in the endoscopy unit and were discharged when stable.

Preparation of specimen for on-site analysis
--------------------------------------------

Predominantly air-dried and a few alcohol-stained smears were prepared on-site after individual passes. Air-dried smears were stained with Diff-Quick stain (Baxter, McGraw Park, IL, United States) for immediate review by a cytopathologist to ascertain sample adequacy and provide a preliminary diagnosis. Number of passes made was dependent on on-site evaluation for adequacy and diagnosis. In the cytopathology laboratory, alcohol-stained smears were prepared using Papanicolaou's stain; cell block pellets were prepared, sectioned, and stained with routine hematoxylin and eosin. The cytopathologist then characterized the diagnosis into previously described [@JR362-15] cytopathologic categories: positive for malignancy; negative for malignancy; atypical; suspicious; benign and non-diagnostic after additional review of slides.

Preparation of cellblock for histological analysis
--------------------------------------------------

The EUS-FNA specimen was placed in Cytolyte and taken to the laboratory where it was spun in the centrifuge. After decanting the supernatant, the sediment was made into a pellet and placed in a Tissue-Loc HistoScreen cassette (Microm International, Walldorf, Germany) and fixed in formalin. Thereafter, it was embedded in paraffin and sections made for hematoxylin and eosin (H&E) staining to examine for the presence of a histological core. Only the diagnostic specimens with definable histological core were included.

Surgical pathology specimens
----------------------------

Once surgery was performed, surgical pathology specimens were analyzed and the final diagnosis recorded in the database. Patients who had histological core tissue acquired at the time of surgical exploration, but were deemed inoperable were also included in the database. Surgically obtained specimens were sectioned and placed in formalin. These were further processed, embedded in paraffin, and stained with hematoxylin and eosin.

Statistical analysis
--------------------

Lesions defined as "malignant" and "suspicious" by EUS-FNA, with a final pathology diagnosis of malignancy, were categorized as True Positive (TP) for applying the Multinominal Logistic Regression (MLR) model; those with benign final diagnosis were categorized as False Positive (FP). Similarly, patients diagnosed as "negative" and "benign" by histology were considered True Negative (TN), whereas those "negative" or "atypical" on EUS-FNA but malignant on surgical pathology were categorized as False Negative (FN). In all of these, only the final cytologic diagnosis was considered in the analysis. Chi-squared tests were used for each categorical variable (sex, location of the mass, final diagnosis, sensitivity) to test their association among the four groups. Analysis of variance (ANOVA) was conducted to compare means of age and the number of FNA passes across all groups. Cochran-Armitage trend tests were performed to examine for increasing or decreasing trends in diagnostic accuracy and sensitivity with tumor size. Pairwise comparisons of absolute difference among the groups were done by Chi-squared tests with Bonferroni adjustment.

As suggested by Dwivedi et al. [@JR362-16], we fitted multinomial logistic regression models for the four outcomes (TP, FP, TN, and FN) with covariates of age, sex, diameter of lesion as measured by EUS, and pancreatic location. We considered two separate models with maximum and minimum diameter of lesion per outcome category. The sensitivity model used false negative as reference value and the specificity model used false positive as reference value. Two-sided *P* values \< 0.05 were considered statistically significant. Analysis was done using SAS software, version 9.3 (SAS Institute Inc., Cary, NC, United States), as well as IBM-SPSS version 22 (Armonk, New York, United States).

Results
=======

A total of 3832 EUS-FNAs were performed during the study period. Of these, 612 patients had histological follow-up. Accurate information with regard to mass size was lacking in 81 cases and these were excluded. The rest (531/3832; 13.9 %, 95 %CI: 12.8 -- 15.0) formed the study cohort ([Fig. 1](#FI362-1){ref-type="fig"}).

![ Flow chart showing the included study subjects.](10-1055-s-0035-1569969-i362ei1){#FI362-1}

Demographics
------------

The groups were evenly matched for age and gender, while there was a significant difference in the location of the mass with predominant lesions noted in the head of pancreas (*P* = 0.0002). Final diagnosis revealed a significant proportion of ductal adenocarcinoma (*P* \< 0.0001). The results are shown in [Table 1](#TB362-1){ref-type="table"}.

###### Patient characteristics and EUS findings for the entire cohort.

                                Group A (n = 15)   Group B (n = 112)   Group C (n = 328)   Group D (n = 76)   P value
  ----------------------------- ------------------ ------------------- ------------------- ------------------ -----------
  Age, mean (SD), years         65 (4)             67 (7)               67 (9)             64 (12)            0.0564
  Sex, n (%)                                                                                                  0.8811
   Male                          6 (40)            56 (50)             165 (50)            37 (49)            
   Female                        9 (60)            56 (50)             163 (50)            39 (51)            
  Location, n (%)                                                                                             0.0002
   Uncinate                      --                14 (13)              37 (11)             5 (7)             
   Head                          9 (60)            70 (62)             196 (60)            32 (42)            
   Body                          4 (27)            20 (18)              39 (12)            12 (16)            
   Tail                          2 (13)             8 (7)               56 (17)            27 (35)            
  Number of passes, mean (SD)    2.2 (1.7)          3 (2.1)              2.8 (1.8)          3.5 (1.9)         0.0124
  Final diagnosis, n (%)                                                                                      \< 0.0001
   Adenocarcinoma                7 (47)            79 (70)             225 (69)            28 (37)            
   Neuroendocrine tumor          4 (27)            15 (13)              24 (7)              6 (8)             
   Lymphoma                      --                 1 (1)                9 (3)              8 (10.5)          
   Chronic pancreatitis          --                 6 (5)               31 (9)              8 (10.5)          
   Others                        4 (26)            11 (11)              39 (12)            26 (34)            

Operating characteristics of EUS-FNA
------------------------------------

The overall sensitivity was 85.95 %, diagnostic accuracy was 86.44 % and with a positive predictive value of 98.8 % ([Table 2](#TB362-2){ref-type="table"}). The mean number passes of 2.2 (SD 1.7), 3 (SD 2.1), 2.8 (SD 1.8), and 3.5 (SD 1.9) required for on-site diagnosis ([Fig. 2](#FI362-2){ref-type="fig"}) between the four groups was statistically significantly different (*P* = 0.0124). There was no significant relationship between the four groups and sensitivity (*P* = 0.1134). The Cochran-Armitage trend test did not reveal an increasing or decreasing trend in diagnostic accuracy (*P* = 0.9923) or the probability of finding a true positive result in relation to tumor size (*P* = 0.6192).

###### Operating characteristics of EUS-FNA between the groups.

                        Group A   Group B   Group C   Group D   Total
  --------------------- --------- --------- --------- --------- --------
  Sensitivity           0.7333    0.8738    0.8776    0.7846    0.8595
  Diagnostic accuracy   0.7333    0.8661    0.8811    0.8158    0.8644

![ Bar chart depicting the mean number of passes required for on-site diagnosis between the four groups.](10-1055-s-0035-1569969-i362ei2){#FI362-2}

As shown in [Table 3](#TB362-3){ref-type="table"} and [Table 4](#TB362-4){ref-type="table"}, the maximum diameter of lesion measured by EUS was not associated with sensitivity or specificity after adjusting for age, sex, and pancreatic location. We observed similar results from the models with the minimum diameter of lesion (not presented). The models for positive predictive value (PPV) and negative predictive value (NPV) showed similar results in terms of significance of the size of lesion (not presented).

###### Parameter estimates for sensitivity model with maximum diameter of lesion.

                               Adjusted odds ratio (OR)   P value   95 %CI for adjusted OR
  ---------------------------- -------------------------- --------- ------------------------
  Age                          1.01                       0.543     0.97 -- 1.03
  Maximum diameter of lesion   0.94                       0.546     0.78 -- 1.14
  Female                       0.96                       0.890     0.57 -- 1.64
  Pancreatic location                                               
  Uncinate                     1                                    
  Head                         0.72                       0.509     0.27 -- 1.93
  Body                         0.61                       0.419     0.19 -- 2.00
  Tail                         1.27                       0.698     0.38 -- 4.26

###### Parameter estimates for specificity model with maximum diameter of lesion.

                                                           Adjusted odds ratio (OR)   P value   95 %CI for adjusted OR
  -------------------------------------------------------- -------------------------- --------- ------------------------
  Age                                                      0.97                       0.401     0.89 -- 1.05
  Maximum diameter of lesion                               2.01                       0.187     0.70 -- 6.14
  Female                                                   0.64                       0.649     0.09 -- 4.43
  Pancreatic location[\*](#FN362-1){ref-type="table-fn"}                                        
  Body                                                     0.66                       0.771     0.04 -- 11.06
  Head                                                     3.36                       0.370     0.24 -- 47.56
  Uncinate                                                 1                                    

Categories of tail in pancreatic location were dropped because the frequency was very small or zero.

Discussion
==========

This study determined that, under controlled, gold standard conditions, the performance of EUS-FNA is unaffected by pancreatic mass size and confirmed that, to obtain an on-site diagnosis, an increasing number of passes is required for larger lesions.

Siddiqui et al. [@JR362-12] showed that diagnostic accuracy and sensitivity were strongly correlated with tumor size with a significant reduction for tumors less than 10 mm; however, in that study, the number of cases in each group was not reported, on-site assessment was rendered by a cytotechnician, and follow-up criteria included clinical review. In another multicenter study, Sahai et al. [@JR362-11] concluded that the image quality and/or depth of penetration were insufficient to permit successful FNA of smaller lesions. However, that study was performed with a mechanical sector-scanning transducer without Doppler capability, not all centers that participated in the study had rapid on-site evaluation, and FNA passes were restricted to less than three. In contrast, our decade long experience is with curvilinear array echoendoscopes in the presence of ROSE, the number of passes made was smaller, and we used histological follow-up exclusively. In the last decade, advancements in echoendoscope technology and needle designs have allowed the endosonographer to accurately target even deeply placed small lesions with greater efficiency and accuracy. Since a small mass is a concentrated, dense area of abnormal cells with no necrosis, suitably targeted FNA often provides "excellent" material with minimal contamination. Sample adequacy is tested immediately by ROSE and, if negative, care is taken to ensure suitable needle placement inside the lesion for subsequent passes to achieve an accurate diagnosis.

Erickson et al. reported that the presence of a cytopathologist during EUS-FNA improves diagnostic yield, decreases the number of unsatisfactory samples, reduces the need for more passes, and consequently, the procedural duration [@JR362-17]. Our experience reflects that study as the mean number of passes for on-site diagnosis for the whole cohort was 2.6. In a recent meta-analysis, Hebert-Magee et al. showed that the presence of ROSE increases the diagnostic accuracy of EUS-FNA for pancreatic adenocarcinoma but lower performance was seen when histology alone was taken as the gold standard while this was higher for studies with clinical follow-up [@JR362-7]. This may explain the low rates noted in our data in comparison to other studies. ROSE is a vital feature as good communication, team work, and interdisciplinary collaboration are crucial for obtaining an on-site diagnosis. The presence of ROSE helps not only in reducing the number of passes, but also improving overall diagnostic accuracy [@JR362-17]; that study also showed that EUS-FNA performance is unaffected by pancreatic mass size.

In a randomized trial of 54 patients with solid pancreatic mass lesions, the fanning technique established a significantly higher first pass diagnosis in 85.7 % of patients compared to only 57.7 % with the standard technique [@JR362-18]. That study highlighted the importance of technique as a key factor for successful tissue procurement. It is well documented that larger lesions tend to have necrotic material in the center of the lesion and targeting the periphery yields adequate tissue for diagnosis [@JR362-19]. Our data reflect other previously noted observations [@JR362-12] [@JR362-20] that multiple passes are required for larger lesions to make a diagnosis. However, randomized data in the presence of ROSE and the fanning technique indicate that on-site diagnosis can be achieved in a majority with a single pass [@JR362-17] [@JR362-21] [@JR362-22]. Another randomized trial comparing 19G vs. 25G FNA needles also showed that on-site diagnostic adequacy can be achieved in more than 97 % with a single pass even in large pancreatic lesions [@JR362-23]. These studies also showed that, in the presence of ROSE, when a structured fanning technique is adopted, diagnosis can be achieved in a significant majority with a single pass independent of needle or pancreatic mass sizes.

Our study had several limitations. First, the number of pancreatic masses in group A was small which may have had an impact on the results; this, however, reflects the strict histopathology criteria adopted in this study. Second, the procedure was performed by experienced endosonographers, without trainee involvement, with proficient and expert on-site cytopathologists in attendance; therefore, the results may not be applicable to all units and if trainees were involved. Third, only patients who underwent index FNA were included in the analysis while patients who underwent repeat EUS-FNA for high clinical suspicion were excluded; the results may be vastly different if these were included in the analysis. Fourth, there is a likelihood of verification bias within the dataset that precluded complete specificity analysis. Fifth, needle size and pathology subcategory stratification analysis could not be performed due to small size and inconsistent data availability. Finally, this is a retrospective study and has its attendant inadequacies; however, unlike other studies of EUS-FNA, the strength of this study lies in the stringent criteria used for follow-up.

In conclusion, this study shows that in the presence of ROSE, pancreatic mass size does not affect the performance of EUS-FNA, even when final histology is taken as gold standard. This further emphasizes the effectiveness of obtaining an on-site diagnosis.
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